Search company, investor...

OncoBay Clinical

Founded Year



Corporate Majority | Acquired

About OncoBay Clinical

OncoBay Clinical operates a research organization specializing in immuno-oncology and cellular therapy. It offers full-service custom CRO solutions for pharmaceutical and biotech companies. The company was founded in 2019 and is based in Tampa, Florida. In January 2023, NEUCA acquired a majority stake in OncoBay Clinical. The terms of the transaction were not disclosed.

Headquarters Location

10902 McKinley Drive

Tampa, Florida, 33612,

United States


Missing: OncoBay Clinical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: OncoBay Clinical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest OncoBay Clinical News

OncoBay Clinical Frequently Asked Questions (FAQ)

  • When was OncoBay Clinical founded?

    OncoBay Clinical was founded in 2019.

  • Where is OncoBay Clinical's headquarters?

    OncoBay Clinical's headquarters is located at 10902 McKinley Drive, Tampa.

  • What is OncoBay Clinical's latest funding round?

    OncoBay Clinical's latest funding round is Corporate Majority.

  • Who are the investors of OncoBay Clinical?

    Investors of OncoBay Clinical include NEUCA.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.